Systemic mastocytosis (SM) is a condition associated with a clonal neoplastic proliferation of mast cells. Approximately 40% of patients with SM present with an associated clonal hematological non-mast cell lineage disorder. Patients presenting with SM-acute myeloid leukemia (AML) have the worst prognosis. We present a case of a 62-year-old woman who was diagnosed with SM-AML. After initial treatment with a standard regimen of cytosine arabinoside (Ara-C)/idarubicin, her bone marrow showed residual blasts. She was subsequently treated with a second induction regimen of clofarabine and high-dose Ara-C, which resulted in remission of AML, although a residual mast cell infiltrate persisted in her bone marrow. After consolidation therapy with clofarabine/Ara-C, the patient received a stem cell allograft. A follow-up bone marrow showed no residual blasts but persistent mast cells occupying about 5% of the marrow volume.
M
astocytosis is a clonal neoplastic proliferation of mast cells that accumulate in one or more organ systems. According to the latest classifi cation from the World Health Organization, there are seven subtypes of mastocytosis (1) . Th e second most common type of mastocytosis is known as systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disorder (SM-AHNMD). Th ese non-mast cell lineage disorders may include myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), acute myeloid leukemia (AML), chronic myelogenous leukemia, MDS/MPN, plasma cell myeloma, non-Hodgkin lymphoma, and unclassifi able myelogenous malignancy (2) . An associated AML has the worst prognosis (3). We present a case of mastocytosis associated with an AML and discuss the pathology and treatment.
PATIENT DESCRIPTION
A 62-year-old white woman was noted to have a pancytopenia 3 years prior to admission. Her hematocrit was 30%, white blood cell count 3300 K/uL with 44% neutrophils, and platelet count 109,000 K/uL. Bone marrow biopsy revealed trilinear maturation without an abnormal infi ltrate and normal cytogenetics and fl ow cytometry. Her spleen was enlarged, and the liver was infi ltrated by adipose tissue. Her body mass index was 25.1 kg/m 2 . She was believed to have steatohepatitis with pancytopenia secondary to hypersplenism. 
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Leah Zhrebker, MD, Barry Cooper, MD, and John R. Krause, MD Two years later, her pancytopenia and splenomegaly were unchanged. She now had fatigue, dyspnea, and fever (99°F) for 2 weeks. Her white blood cell count was 63,000/mm 3 with 38% circulating blasts, hematocrit 27%, and platelets 57,000/mm 3 . A bone marrow biopsy showed 50% infi ltration with mast cells and 50% myeloblasts, confi rming the entity of SM-AHNMD ( Figure 1 ). Results of an AML fl uorescent in situ hybridization panel and routine cytogenetics were negative. She had a C-KIT D816V mutation but no JAK-2 mutation. Her serum tryptase level was 189 ng/mL (normal level, <11.4).
Th e patient was admitted to the hospital and underwent induction chemotherapy with cytosine arabinoside (Ara-C) (100 mg/m 2 /day by continuous infusion for 7 days) and idarubicin (12 mg/m 2 /day for 3 days). She was also started on dasatinib at 100 mg orally daily. Bone marrow biopsy 14 days after induction of treatment revealed persistent myeloblasts and mast cell infi ltrate requiring a second course of therapy with 5 days of high-dose Ara-C (1 g/m 2 /day) and clofarabine (40 mg/ m 2 /day). Because of the persistent mast cell infi ltrate, dasatinib was discontinued. Her blood counts recovered on discharge, except for a platelet count of 40,000 K/uL. Her white blood cell count was 8,900 K/uL, and her hematocrit was 32.2%.
Repeat bone marrow biopsy showed no residual myeloblasts, with residual mast cells of 15%. Her tryptase level decreased to 77 ng/mL. She was readmitted 3 weeks later for consolidation chemotherapy with clofarabine/Ara-C. Four weeks later she had a stem cell allograft using an unrelated donor with a preparative regimen of busulfan and cyclophosphamide. Follow-up marrow revealed no evidence of AML, 5% residual mast cell infi ltrate, and focal increased reticular fi brosis.
DISCUSSION
Th e diagnosis of SM-AHNMD may be diffi cult to establish, as the histologic and cytologic features of systemic mastocytosis Systemic mastocytosis with associated acute myelogenous leukemia (SM) may be masked by the associated malignancy. Th e diagnosis can only be made when there is clear morphologic evidence of both SM with multifocal tissue infi ltrates and an AHNMD, as in this case (4) . Malignant mast cells may abnormally express CD2 and/or CD25, which may be detected by immunochemistry or fl ow cytometry. Th is is helpful in distinguishing neoplastic mast cells (CD25 + and/or CD2 + ) from reactive mast cells (CD2 − and CD25 − ). Activating c-kit mutations are considered the hallmark of neoplastic mast cells (5) .
Th e pathogenesis of SM associated with AHNMD is unknown, and the non-mast cell lineage component might or might not show evidence of the same c-kit mutation seen in the neoplastic mast cells. When there is an associated myeloid neoplasm, there are two proposed theories for the pathogenesis. One theory involves an activating c-kit mutation that occurs with other genetic mutations and events in a myeloid stem cell (6, 7) . Th e c-kit mutation could result in a proliferative advantage to the mutated stem cell and lead to mast cell diff erentiation and proliferation (8) . Another possible mechanism is transformation of a subclone of the myeloid progenitor cells through an acquired c-kit mutation resulting in a coexisting mastocytosis (9) . Th e association with c-kit mutations in SM associated with lymphoid neoplasms is even less apparent, as mutations have not been reported in these cases.
It is important to distinguish SM-AHNMD from other entities associated with mast cell diff erentiation. Th ese include tryptase-positive AML, MDS with prominent involvement of the mast cell lineage, and systemic mastocytosis associated with the hypereosinophilic syndrome and myeloproliferative disorders associated with PDGFRA or PDGFRB fusion genes. None of the aforementioned entities would be classifi ed as SM-AHNMD. Among patients with SM-AHNMD, those with SM-MPN have a signifi cantly longer median survival than patients with SM-CMML (chronic myelomonocytic leukemia), SM-MDS, and SM-AML, which has the worst prognosis (3).
We initially treated our patient with a standard AML regimen of Ara-C/idarubicin, adding dasatinib, which has been reported to induce apoptosis of leukemia cells expressing c-KIT. Th e combination of drugs induced molecular remission in a similar patient reported by Ustun et al (10) . Clofarabine was added along with a second course of Ara-C when persistent disease was found after the initial cycle of therapy. Phase II studies from M. D. Anderson Center as well as Baylor University Medical Center at Dallas showed that the combination of clofarabine and Ara-C is eff ective in both untreated and previously treated patients with AML and can serve as a bridge to transplantation in older patients with AML. Our patient did achieve a complete remission of AML with this regimen, albeit there was a persistent mast cell infi ltrate. Clofarabine is an adenosine deaminase analog similar to fl udarabine and cladribine. In fact, cladribine as a single agent is an eff ective drug to treat systemic mastocytosis, with all nine patients treated with this drug having a partial response, as reported by Hanneke at al (11) . Finally, in our patient there was a further decrease in the mast cell infi ltrate 4 weeks after transplant. 
